First, let’s get one thing straight. There is no “crisis.”
Now that Novartis, GlaxoSmithKline, AstraZeneca, Merck, and Sanofi have either scaled back or (in the case of GSK and AZ) abandoned any further Central Nervous System (CNS) R&D, the hand-wringing has begun, with distinguished professors like Dr. Steven E. Hyman writing alarmist editorials about the imperiled future of psych meds and articles in the media talking of a “crisis” in psych-med research. (The opening sentence of a recent editorial in Schizophrenia Bulletin was: “Psychopharmacology is in crisis.” The headline of Dr. Hyman’s piece is “Psychiatric Drug Development: Diagnosing a Crisis.”)
First, let’s get one thing straight. There is no “crisis.” A review of the new-drug pipeline shows that 137 active R&D programs have 417 ongoing development projects aimed at 19 psychiatric indications. Most of these programs are in Phase I or II trials. Psych-med R&D is more vigorous than ever.
The widely reported shutdown of CNS research programs at GSK and AZ (and the scale-backs at Pfizer and elsewhere) represent the continuation of a process begun long ago, to outsource riskier types of development to academia (which gets funding from the drug companies as well as government, via NIH and NMIH) and to smaller, less risk-averse drug companies (including startups) who eventually sell their projects back to the giant pharmas, once it looks like they’ve “got something.”
But the whole notion that a GSK or an AstraZeneca can convert R&D dollars into brand-new, never-tried-before, fundamentally innovative psych meds is ridiculous in the first place, because that’s not how development of new treatments works. You can only develop a targeted drug when you know the precise biochemical mechanism of action of the underlying disease. That’s not the case for depression, schizophrenia, or any of the other major psychiatric illnesses. As H. Christian Fibiger correctly points out in his Schizophrenia Bulletin piece:
The discovery of all three major classes of psychiatric drugs, antidepressants, antipsychotics, and anxiolytics, came about on the basis of serendipitous clinical observation. At the time of their discoveries, the mechanisms by which these molecules produce their effects were unknown, and it was only later that antipsychotics were shown to be D2 receptor antagonists, antidepressants monoamine reuptake inhibitors, and anxiolytics GABA receptor modulators. It is interesting and perhaps instructive to consider whether any of these classes of drugs could have been discovered by current drug discovery strategies. For example, what genetic or preclinical data exist that point to the D2 dopamine receptor as a likely target for antipsychotic activity? Presently there are no genetic data that suggest that this receptor is expressed or functions abnormally in psychotic disorders. And without the benefit of the prior clinical validation, it is difficult to see how preclinical data alone would point to the D2 receptor as an interesting potential target for the treatment of psychotic disorders. The same can be said for monoamine transporters with respect to depression where, like psychosis, there are no animal models based on disease pathophysiology and no compelling preclinical data pointing to these as potential targets for antidepressant drugs.
The best Big Pharma has been able to do over the years is craft me-too drugs once a serendipitous discovery has been made. But the serendipitous discoveries themselves (such as John Cade‘s discovery that injecting Guinea pigs with lithium urate made them placid) can’t be manufactured; they can’t be bought. They happen by accident.
The Latest Bing News on:
Psychiatric Drug Development
- Psychedelic use is only “weakly” associated with psychosis-like symptoms, according to new researchon January 17, 2022 at 6:00 am
People who take psychedelics are more likely to report psychosis-like symptoms, but this is largely explained by the presence of other mental health conditions and the use of other psychoactive drugs.
- The link between brain cell development and psychiatric disorderson January 17, 2022 at 2:13 am
Scientists have discovered new links between brain cell development and the risk of schizophrenia and other psychiatric disorders.
- American Psychiatric Nurses Association Opens Call for Abstracts for 2022 APNA Annual Conferenceon January 14, 2022 at 1:06 am
APNA is seeking abstract proposals for both podium and poster presentations that address all levels of psychiatric-mental health nursing administration, education, practice, and research. The APNA ...
- The return of psychiatric neurosurgery: can it be ethical this time?on January 13, 2022 at 5:38 am
Neurosurgical psychiatric techniques, such as Deep Brain Stimulation (DBS), are reviving in popularity as subjects of inquiry and research. But regarding the controversial history of psychiatric ...
- Investigational New Drug Clearance Given to R-Ketamineon January 12, 2022 at 10:36 am
The FDA has given Investigational New Drug clearance for a clinical drug-drug interaction study of R-ketamine (PCN-101).
- Psychiatrists Wake Up to Criticisms of Their Industry and the Demands for Patients to be Protected from Psychiatric Abuseon January 11, 2022 at 3:14 pm
CCHR says its exposure of corruption and abuses in the mental health industry spurs much-needed debate about "traumatized, disenchanted, and devastated" patients.
- Delix Therapeutics Raises $30M In Convertible Note Financing, Will Enhance Drug Development Programon January 11, 2022 at 9:17 am
Delix Therapeutics, a neuroscience company developing novel therapeutics for psychiatric and neurological conditions, announced Monday that it has raised over ...
- The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicineson January 5, 2022 at 4:00 am
The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. (Mindset) (CSE: MSET) (FSE: 9DF) (OTCQB ...
- Mindset Pharma Recaps 2021 Milestones and Highlightson December 30, 2021 at 3:34 am
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders ...
- Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatryon December 24, 2021 at 7:53 am
Approach expected to rapidly advance the development of ... 2 studies to evaluate the novel drug candidates being developed by Alto Neuroscience for various psychiatric conditions.
The Latest Google Headlines on:
Psychiatric Drug Development
The Latest Bing News on:
Drug research and development
- Innocan Pharma Announces the Inauguration of Its Drug Development Lab at Biohouse in the Hadassah Medical Center in Jerusalemon January 17, 2022 at 1:00 pm
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has inaugurated its first and new drug research and development lab at ...
- Drug Development Could Be Accelerated Using New Photonic Effecton January 17, 2022 at 9:58 am
Twisted semiconductor nanostructures turn red light into twisted blue light in minuscule volumes, which may help create chiral drugs.
- The long hunt for the next breakthrough in drug developmenton January 16, 2022 at 9:00 pm
Drug developers all share certain traits: curiosity, an inquiring mind, a need to get to the bottom of unsolved questions and an appreciation for good teamwork.
- CCS partners with BICO to modernize medical research and drug developmenton January 14, 2022 at 9:30 pm
CCS partners with BICO to modernize medical research and drug development: Gaithersburg, Maryland Saturday, January 15, 2022, 11:00 Hrs [IST] The Center for Contemporary Sciences ...
- Worldwide Anxiety Drugs Industry to 2027 - Increasing Development and Commercialization of Anxiety Drugs Presents Opportunitieson January 14, 2022 at 9:15 am
The "Anxiety Drugs Market Research Report by Type, by Application, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
- Center for Contemporary Sciences (CCS) Partners with BICO to Modernize Medical Research and Drug Developmenton January 13, 2022 at 10:52 am
Today, the Center for Contemporary Sciences (CCS) and BICO formalized a strategic partnership aiming at modernizing drug development and replacing animal testing with more human-relevant methods. CCS ...
- Drug Discovery Informatics Market size worth $ 6.25 Billion, Globally, by 2028 at 11.3% CAGR: Verified Market Research®on January 12, 2022 at 5:15 am
Verified Market Research recently published a report, "Drug Discovery Informatics Market" By Mode (In-house, Outsourced), By Workflow (Drug Discovery, Drug Development), By ...
- Recombinant Protein Market – Increased investment in research and development on biologic drugs is expected to boost the growth of the marketon January 12, 2022 at 12:26 am
Growing research &development activities on biologic drugs for life threatening disease such as cancer is expected to augment recombinant protein market. According to the International Agency for ...
- Antipsychotic Drugs Market | 2022 – 2030 Research Report Analysis, Future Innovations, Growth Elements, and Recent Developmenton January 11, 2022 at 8:32 pm
Global Healthcare Industry Analysis To 2028, is latest report on Global Antipsychotic Drugs Industry, published by Fortune Business Insights. According to this report Global Antipsychotic Drugs Market ...
- Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targetson January 11, 2022 at 12:30 am
Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group in China and Insilico Medicine ("Insilico"), an end-to-end artificial ...